Published in Expert Rev Vaccines on April 01, 2014
Vaccine-mediated immunity against dengue and the potential for long-term protection against disease. Front Immunol (2014) 0.83
Emergence of human West Nile Virus infection in Sri Lanka. BMC Infect Dis (2015) 0.77
A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations. PLoS One (2016) 0.76
West Nile virus IgM and IgG antibodies three years post- infection. Hippokratia (2015) 0.75
Assessing Interventions to Manage West Nile Virus Using Multi-Criteria Decision Analysis with Risk Scenarios. PLoS One (2016) 0.75
Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine. Vaccine (2016) 0.75
A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers. J Infect Dis (2016) 0.75
Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science (1999) 18.55
Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet (2001) 6.49
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Neurologic manifestations and outcome of West Nile virus infection. JAMA (2003) 4.61
West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med (2006) 3.68
Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis (2003) 3.52
A global perspective on the epidemiology of West Nile virus. Annu Rev Entomol (2008) 3.42
Persistent infection with West Nile virus years after initial infection. J Infect Dis (2010) 3.33
Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis (2005) 3.15
West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ (2003) 3.03
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02
West Nile virus: review of the literature. JAMA (2013) 2.79
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg (2001) 2.67
Persistent shedding of West Nile virus in urine of experimentally infected hamsters. Am J Trop Med Hyg (2005) 2.60
Clinical characteristics and functional outcomes of West Nile Fever. Ann Intern Med (2004) 2.49
Surveillance for human West Nile virus disease - United States, 1999-2008. MMWR Surveill Summ (2010) 2.47
CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol (2006) 2.44
Acute flaccid paralysis and West Nile virus infection. Emerg Infect Dis (2003) 2.34
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
The continuing spread of West Nile virus in the western hemisphere. Clin Infect Dis (2007) 2.28
Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis (2011) 2.25
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol (2003) 2.13
West Nile virus: Uganda, 1937, to New York City, 1999. Ann N Y Acad Sci (2001) 2.08
Persistent West Nile virus infection in the golden hamster: studies on its mechanism and possible implications for other flavivirus infections. J Infect Dis (2005) 2.03
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
Excretion of West Nile virus in urine during acute infection. J Infect Dis (2013) 1.95
Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur J Immunol (2007) 1.92
THE CUTTER INCIDENT. POLIOMYELITIS FOLLOWING FORMALDEHYDE- INACTIVATED POLIOVIRUS VACCINATION IN THE UNITED STATES DURING THE SPRING OF 1955. I. BACKGROUND. Am J Hyg (1963) 1.91
Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol (2006) 1.91
West nile virus RNA not detected in urine of 40 people tested 6 years after acute West Nile virus disease. J Infect Dis (2010) 1.88
Phylogeography of West Nile virus: from the cradle of evolution in Africa to Eurasia, Australia, and the Americas. J Virol (2010) 1.88
West Nile virus economic impact, Louisiana, 2002. Emerg Infect Dis (2004) 1.83
Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010. Epidemiol Infect (2012) 1.78
West Nile virus infection: a new acute paralytic illness. Neurology (2003) 1.78
The long-term outcomes of human West Nile virus infection. Clin Infect Dis (2007) 1.77
Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann Neurol (2003) 1.72
A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A (2006) 1.72
A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis (2007) 1.68
Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine (2005) 1.67
The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: the potential for emergent viruses. Zoonoses Public Health (2009) 1.67
Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol (2009) 1.65
West Nile virus-associated flaccid paralysis. Emerg Infect Dis (2005) 1.64
Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol (2000) 1.64
Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nat Biotechnol (2008) 1.64
Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis (2002) 1.64
The structural immunology of antibody protection against West Nile virus. Immunol Rev (2008) 1.63
Immunization of mice against West Nile virus with recombinant envelope protein. J Immunol (2001) 1.60
A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. Virology (2006) 1.54
First Isolation of West Nile virus from a patient with encephalitis in the United States. Emerg Infect Dis (2002) 1.50
ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol (2004) 1.50
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine (2009) 1.48
Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis (2004) 1.46
A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis (2011) 1.42
West Nile encephalitis in Israel, 1999: the New York connection. Emerg Infect Dis (2001) 1.39
Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort. PLoS One (2012) 1.37
DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus. Proc Natl Acad Sci U S A (2003) 1.37
Equine vaccine for West Nile virus. Dev Biol (Basel) (2003) 1.37
Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine (2006) 1.36
Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol (1973) 1.35
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg (2002) 1.35
Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999-2008. Emerg Infect Dis (2012) 1.35
Economic cost analysis of West Nile virus outbreak, Sacramento County, California, USA, 2005. Emerg Infect Dis (2010) 1.34
A recombinant envelope protein vaccine against West Nile virus. Vaccine (2005) 1.31
West Nile fever characteristics among viremic persons identified through blood donor screening. J Infect Dis (2010) 1.26
Development of a new hydrogen peroxide–based vaccine platform. Nat Med (2012) 1.24
Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J Immunol (2007) 1.24
A live attenuated West Nile virus strain as a potential veterinary vaccine. Viral Immunol (2000) 1.24
Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine (2006) 1.21
Review of accidents caused by incomplete inactivation of viruses. Dev Biol Stand (1993) 1.20
Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology (2003) 1.19
Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine (2011) 1.18
The future of human DNA vaccines. J Biotechnol (2012) 1.18
Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One (2008) 1.16
A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med (2006) 1.14
An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development. Virology (2004) 1.14
A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J Infect Dis (2011) 1.13
Delayed mortality in a cohort of persons hospitalized with West Nile virus disease in Colorado in 2003. Vector Borne Zoonotic Dis (2011) 1.13
Severe West Nile virus disease in healthy adults. Clin Infect Dis (2003) 1.12
The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine (2008) 1.10
Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. J Infect Dis (2004) 1.10
TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol (2010) 1.09
Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine (2008) 1.09
Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses. Clin Exp Vaccine Res (2013) 1.07
Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg (2005) 1.06
West nile virus in the United States - a historical perspective. Viruses (2013) 1.05
Cost-effectiveness of West Nile virus vaccination. Emerg Infect Dis (2006) 1.04
Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine (2009) 1.03
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J (2010) 1.03
Wanted, dead or alive: new viral vaccines. Antiviral Res (2009) 1.02
The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol (1995) 1.02
West Nile virus lineage 2 from blood donor, Greece. Emerg Infect Dis (2012) 0.99
West Nile virus, Texas, USA, 2012. Emerg Infect Dis (2013) 0.98
A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J Virol (2012) 0.98
Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol (1997) 0.98
Duration of antiviral immunity after smallpox vaccination. Nat Med (2003) 7.39
Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med (2007) 6.13
The many important facets of T-cell repertoire diversity. Nat Rev Immunol (2004) 3.83
Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med (2005) 2.57
Immunity and immunological memory following smallpox vaccination. Immunol Rev (2006) 2.57
Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev (2010) 1.99
Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J Virol (2002) 1.92
Protective immunity following vaccination: how is it defined? Hum Vaccin (2008) 1.70
How do viral infections predispose patients to bacterial infections? Curr Opin Infect Dis (2004) 1.60
Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology (2011) 1.53
Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition. Cell Host Microbe (2009) 1.47
Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol (2002) 1.42
Quantitation of rare memory B cell populations by two independent and complementary approaches. J Immunol Methods (2006) 1.41
Regulation of innate CD8+ T-cell activation mediated by cytokines. Proc Natl Acad Sci U S A (2012) 1.38
Cytokine-mediated programmed proliferation of virus-specific CD8(+) memory T cells. Immunity (2012) 1.31
Activation of virus-specific CD8+ T cells by lipopolysaccharide-induced IL-12 and IL-18. J Immunol (2004) 1.30
Development of a new hydrogen peroxide–based vaccine platform. Nat Med (2012) 1.24
Murine cytomegalovirus interference with antigen presentation has little effect on the size or the effector memory phenotype of the CD8 T cell response. J Immunol (2004) 1.20
The rapidity with which virus-specific CD8+ T cells initiate IFN-gamma synthesis increases markedly over the course of infection and correlates with immunodominance. J Immunol (2004) 1.12
Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Arch Immunol Ther Exp (Warsz) (2006) 1.11
Cowpox virus evades CTL recognition and inhibits the intracellular transport of MHC class I molecules. J Immunol (2007) 1.09
Differential regulation of virus-specific T-cell effector functions following activation by peptide or innate cytokines. Blood (2004) 1.04
Wanted, dead or alive: new viral vaccines. Antiviral Res (2009) 1.02
Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitis. J Allergy Clin Immunol (2011) 1.01
Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence. J Virol (2011) 0.98
A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J Virol (2012) 0.98
Public fear of vaccination: separating fact from fiction. Viral Immunol (2005) 0.95
Quantifying viable virus-specific T cells without a priori knowledge of fine epitope specificity. Nat Med (2006) 0.92
Pivotal advance: CTLA-4+ T cells exhibit normal antiviral functions during acute viral infection. J Leukoc Biol (2007) 0.92
Antiviral immunity following smallpox virus infection: a case-control study. J Virol (2010) 0.90
GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination. PLoS One (2011) 0.90
Monkeypox virus evades antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation. Proc Natl Acad Sci U S A (2008) 0.89
A cell-intrinsic requirement for NF-κB-inducing kinase in CD4 and CD8 T cell memory. J Immunol (2013) 0.89
The regulation and maturation of antiviral immune responses. Adv Virus Res (2004) 0.86
Retrospective analysis of monkeypox infection. Emerg Infect Dis (2008) 0.86
Longevity of T-cell memory following acute viral infection. Adv Exp Med Biol (2010) 0.84
Monkeypox without exanthem. N Engl J Med (2007) 0.84
Serologic evidence for novel poxvirus in endangered red Colobus monkeys, Western Uganda. Emerg Infect Dis (2008) 0.84
Traditional smallpox vaccination with reduced risk of inadvertent contact spread by administration of povidone iodine ointment. Vaccine (2007) 0.83
Characterization of CD8+ T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine. J Virol (2012) 0.83
T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. JCI Insight (2017) 0.82
CD8+ T cell immunodominance shifts during the early stages of acute LCMV infection independently from functional avidity maturation. Virology (2009) 0.81
Cutaneous responses to vaccinia in individuals with previous smallpox vaccination. J Am Acad Dermatol (2007) 0.81
Impact of infection or vaccination on pre-existing serological memory. Hum Immunol (2012) 0.80
Preformed CD40L is stored in Th1, Th2, Th17, and T follicular helper cells as well as CD4+ 8- thymocytes and invariant NKT cells but not in Treg cells. PLoS One (2012) 0.80
Optimization of peptide-based ELISA for serological diagnostics: a retrospective study of human monkeypox infection. Vector Borne Zoonotic Dis (2012) 0.78
A flow cytometry-based assay for quantifying non-plaque forming strains of yellow fever virus. PLoS One (2012) 0.77
Antibody-mediated protection against respiratory viral infection. Semin Respir Crit Care Med (2005) 0.76
The immunostimulatory power of acute viral infection. Immunity (2008) 0.76
Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG. Transplantation (2013) 0.75
Editorial: Profiling senescent influenza-specific T cells in the elderly. J Leukoc Biol (2013) 0.75
Keystone conference on viral immunity: from basic mechanisms to vaccines (X7) and advances in influenza research: from birds to bench to bedside (X8) Steamboat Springs, Colorado March 28-April 2, 2006. Viral Immunol (2006) 0.75
CTLA4, T cell function, and long term immunity: an interview with Dr. Mark K. Slifka. Interview by Helene F. Rosenberg. J Leukoc Biol (2007) 0.75